UA109359C2 - Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном - Google Patents

Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном

Info

Publication number
UA109359C2
UA109359C2 UAA201406109A UAA201406109A UA109359C2 UA 109359 C2 UA109359 C2 UA 109359C2 UA A201406109 A UAA201406109 A UA A201406109A UA A201406109 A UAA201406109 A UA A201406109A UA 109359 C2 UA109359 C2 UA 109359C2
Authority
UA
Ukraine
Prior art keywords
skin diseases
states
treatment
effective amount
therapeutically effective
Prior art date
Application number
UAA201406109A
Other languages
English (en)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178364&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA109359(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UA109359C2 publication Critical patent/UA109359C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
UAA201406109A 2011-11-10 2012-08-11 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном UA109359C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558104P 2011-11-10 2011-11-10
PCT/US2012/064075 WO2013070861A1 (en) 2011-11-10 2012-11-08 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Publications (1)

Publication Number Publication Date
UA109359C2 true UA109359C2 (xx) 2015-08-10

Family

ID=47178364

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201406109A UA109359C2 (xx) 2011-11-10 2012-08-11 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном

Country Status (21)

Country Link
US (4) US20130123303A1 (ru)
EP (3) EP2776034B1 (ru)
JP (2) JP6359456B2 (ru)
KR (1) KR102004563B1 (ru)
CN (1) CN104136029A (ru)
AR (1) AR088845A1 (ru)
AU (2) AU2012335803B2 (ru)
BR (1) BR112014011336A2 (ru)
CA (1) CA2855005C (ru)
CL (1) CL2014001242A1 (ru)
DK (1) DK2776034T3 (ru)
ES (1) ES2635421T3 (ru)
IL (3) IL232483B (ru)
MX (1) MX350662B (ru)
MY (1) MY182553A (ru)
RU (2) RU2630978C2 (ru)
SG (3) SG10201609145PA (ru)
TW (3) TWI708604B (ru)
UA (1) UA109359C2 (ru)
WO (1) WO2013070861A1 (ru)
ZA (1) ZA201403396B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
KR20160005351A (ko) * 2013-05-06 2016-01-14 알러간, 인코포레이티드 조직 외상의 치료를 위한 알파 아드레날린 작용제
FR3061434B1 (fr) * 2017-01-04 2019-07-12 Pierre Fabre Dermo-Cosmetique Composition cosmetique comprenant une association d'huile de pongamia et de pentylene glycol 4-t-butylcyclohexanol pour lutter contre la rosacee
RU2727695C1 (ru) * 2020-02-13 2020-07-22 Мурад Умарович Магомедов Способ комплексного лечения ринофимы

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1075265T3 (da) * 1998-05-08 2006-06-26 Univ Miami Anvendelse af tetracycliner til behandling af sygdom i de Meibomske kirtler
WO2004073708A1 (en) * 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
WO2005051328A2 (en) * 2003-11-20 2005-06-09 Othera Pharmaceuticals, Inc. Amelioration of macular degeneration and other ophthalmic diseases
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
PL1761266T3 (pl) * 2004-05-25 2013-09-30 Galderma Pharma Sa Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
US7323477B2 (en) 2006-02-02 2008-01-29 Allergan, Inc. 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
RU2321399C1 (ru) * 2006-06-01 2008-04-10 Федеральное государственное учреждение "Нижегородский научно-исследовательский кожно-венерологический институт Федерального агентства по здравоохранению и социальному развитию" Способ лечения больных розацеа
US20090005450A1 (en) * 2007-04-09 2009-01-01 Belinda Tsao Nivaggioli Use of creatine compounds for the treatment of eye disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20100029662A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
BR112012009891A2 (pt) * 2009-10-26 2015-09-29 Galderma Pharma Sa métodos para tratar eritema agudo e para prevenir o eritema agudo e uma inflamação secundária em um humano em necessidade do mesmo
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
DK2552449T3 (en) * 2010-03-26 2017-06-19 Galderma Res & Dev COMPOSITIONS INCLUDING BRIMONIDINE FOR TREATMENT OF ERYTHEM
KR20150058551A (ko) * 2010-03-26 2015-05-28 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
CA2810267A1 (en) * 2010-08-06 2012-02-09 Galderma Research & Development Combination of compounds for treating or preventing skin diseases

Also Published As

Publication number Publication date
IL232483B (en) 2018-10-31
IL268757A (en) 2019-10-31
JP6359456B2 (ja) 2018-07-18
AU2012335803A1 (en) 2014-05-29
ES2635421T3 (es) 2017-10-03
CA2855005C (en) 2016-11-22
IL261269A (en) 2018-10-31
MX350662B (es) 2017-09-13
IL232483A0 (en) 2014-06-30
CN104136029A (zh) 2014-11-05
SG10201809506TA (en) 2018-11-29
AR088845A1 (es) 2014-07-10
TWI580424B (zh) 2017-05-01
MY182553A (en) 2021-01-25
AU2012335803B2 (en) 2016-05-26
US20170095466A1 (en) 2017-04-06
NZ624771A (en) 2016-11-25
EP3184110B1 (en) 2020-10-07
MX2014005640A (es) 2014-09-22
US20150231128A1 (en) 2015-08-20
US20160051534A1 (en) 2016-02-25
JP6526737B2 (ja) 2019-06-05
RU2630978C2 (ru) 2017-09-15
EP2776034B1 (en) 2017-03-22
RU2667645C1 (ru) 2018-09-21
CL2014001242A1 (es) 2014-11-14
TWI708604B (zh) 2020-11-01
JP2017149767A (ja) 2017-08-31
TW202014189A (zh) 2020-04-16
KR20140107237A (ko) 2014-09-04
EP3184110A1 (en) 2017-06-28
SG11201402246RA (en) 2014-06-27
US9308201B2 (en) 2016-04-12
BR112014011336A2 (pt) 2017-05-02
SG10201609145PA (en) 2016-12-29
RU2014122758A (ru) 2015-12-20
WO2013070861A1 (en) 2013-05-16
AU2016216627B2 (en) 2017-10-19
DK2776034T3 (en) 2017-07-10
JP2014533271A (ja) 2014-12-11
ZA201403396B (en) 2015-07-29
EP2776034A1 (en) 2014-09-17
EP3763370A1 (en) 2021-01-13
CA2855005A1 (en) 2013-05-16
TW201713338A (zh) 2017-04-16
TW201328694A (zh) 2013-07-16
US20130123303A1 (en) 2013-05-16
KR102004563B1 (ko) 2019-07-26
AU2016216627A1 (en) 2016-09-08

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201890852A1 (ru) Соли валбеназина и их полиморфы
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
MX2009010407A (es) Derivados fluorados de deferiprona.
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
PH12016502352A1 (en) Pharmaceutical composition
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
TW201613578A (en) Pharmaceutical combinations
EA201290603A1 (ru) Способ лечения
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение
IL268757A (en) Pharmaceutical preparations containing 7-(H1-imidazol-4-ylmethyl)-8,7,6,5-tetrahydroquinoline for the treatment of skin diseases and conditions
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
WO2013151719A3 (en) Fluorinated oxazolidinone derivatives
CY1117605T1 (el) Θεραπεια της ασθενειας crohn me laquinimod